GlassScriptPhysician profile
Kimberly Ford
NPI 1205366788
$576.08
in general payments reported to CMS, 2019-2025
14 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $83.13 · 2023: $134 · 2024: $135 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $371.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $103.40 | 2021-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $75.70 | 2021-2024 | |
| Astellas Pharma US INC | $68.45 | 2021-2023 | Veozah |
| Pfizer INC. | $62.05 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $56.43 | 2022-2025 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $45.31 | 2024-2025 | Voquezna |
| Lundbeck LLC | $43.94 | 2023-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $26.46 | 2021-2022 | |
| Irhythm Technologies, INC. | $18.99 | 2023 | Zio Xt Patch |
| Astrazeneca Pharmaceuticals LP | $17.24 | 2024 | Breztri |
| Csl Behring | $15.93 | 2022 | |
| Neurocrine Biosciences, INC. | $15.45 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.88 | 2023 | |
| Glaxosmithkline, LLC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.